Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Cantor Fitzgerald

Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a note issued to investors on Tuesday,Briefing.com Automated Import reports.

Other analysts have also recently issued research reports about the company. Truist Financial dropped their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research report on Friday. Oppenheimer reduced their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Piper Sandler lowered their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Trading Up 3.2 %

Shares of Keros Therapeutics stock opened at $10.86 on Tuesday. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock’s fifty day moving average price is $35.23 and its 200-day moving average price is $46.97. The firm has a market cap of $439.94 million, a P/E ratio of -2.08 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same period in the previous year, the firm earned ($1.33) earnings per share. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. Analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KROS. Renaissance Technologies LLC purchased a new stake in Keros Therapeutics in the second quarter valued at approximately $654,000. XTX Topco Ltd acquired a new stake in Keros Therapeutics during the 2nd quarter valued at approximately $228,000. Point72 DIFC Ltd purchased a new stake in shares of Keros Therapeutics in the 2nd quarter valued at $802,000. Squarepoint Ops LLC purchased a new position in shares of Keros Therapeutics during the second quarter worth $906,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics during the second quarter valued at $128,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.